- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
Patent holdings for IPC class A61P 3/12
Total number of patents in this class: 290
10-year publication summary
|
14
|
11
|
16
|
17
|
21
|
26
|
34
|
14
|
13
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vifor (International) AG | 140 |
10 |
| Ardelyx, Inc. | 113 |
8 |
| Renosis, Inc. | 24 |
8 |
| Banyu Pharmaceutical Co., Ltd. | 72 |
6 |
| Daiichi Sankyo Company, Limited | 1852 |
6 |
| Société des Produits Nestlé S.A. | 9208 |
5 |
| MSD K.K. | 71 |
5 |
| AstraZeneca AB | 2928 |
4 |
| Ajinomoto Co., Inc. | 2298 |
4 |
| Protagonist Therapeutics, Inc. | 137 |
4 |
| Takeda Pharmaceutical Company Limited | 2704 |
3 |
| University of Florida Research Foundation, Inc. | 3989 |
3 |
| Beachbody, LLC | 613 |
3 |
| Chugai Seiyaku Kabushiki Kaisha | 1334 |
3 |
| Kowa Company, Ltd. | 1195 |
3 |
| Mitsubishi Tanabe Pharma Corporation | 578 |
3 |
| Tricida, Inc. | 29 |
3 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 279 |
3 |
| Amilyfe, LLC | 59 |
3 |
| Novartis AG | 10904 |
2 |
| Other owners | 201 |